Risk factor
Very high price volatility
Profitability factor
Strong margins and returns
About
Headquartered in Seoul, South Korea, Pharmicell Co., Ltd. is a biopharmaceutical company established in 2002, actively developing and marketing stem cell treatments across South Korea and globally. The firm operates through two primary segments: Biopharmaceutical Business and Biochemical Business. Its flagship approved product, Cellgram_AMI, leverages a patient's own bone marrow-derived mesenchymal stem cells to enhance heart pumping capacity (ejection fraction) in individuals who have suffered acute myocardial infarction and subsequently undergone coronary angioplasty. Beyond this, Pharmicell is actively progressing several pipeline candidates, including Cellgram_LC for liver ailments, Cellgram_ED targeting impotence, Cellgram_DC for cancer treatment, and Hearticellgram_AM for various cardiac conditions. In its Biochemical division, the company produces crucial intermediates for pharmaceutical raw materials, such as nucleosides, mPEGs, and HDP-tosylate, alongside manufacturing specialized industrial materials like low dielectric constant substances and eco-friendly flame retardants. Furthermore, Pharmicell operates "Twelve," a dedicated stem cell bank, and formulates cosmetics utilizing stem cell culture media.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA,